U.S. FDA Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple ...
Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that six of its latest research studies have been accepted for presentation at the 2026 European ...
Recommendation supported by unprecedented Phase 3 data, demonstrating that TECVAYLI® in combination with daratumumab achieved statistically significant improvements in progression-free and overall ...
Bristol Myers Squibb’s New Drug Application (NDA) for mezigdomide has been accepted by the US FDA. Mezigdomide is an oral ...
Vietnam Investment Review on MSN
Leads Biolabs gets six studies selected for ESMO 2026
NANJING, China, July 13, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that six of its latest research studies have been ...
Professor Ogbonna Collins Nwabuko has called for stronger responses to Africa’s health challenges, saying disease outcomes ...
Gilead's expansion beyond HIV therapies will surprise many investors.
Karyopharm (KPTI) downgraded to Hold amid weak XPOVIO sales, FDA setbacks, and mixed SENTRY data. Click here to read my most ...
Johnson & Johnson (NYSE:JNJ) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript ...
Q2 2026 Earnings Call July 15, 2026 8:30 AM EDTCompany ParticipantsRyan KoorsJoaquin Duato - CEO & ChairmanJoseph Wolk ...
Cochlear Limited , the global leader in implantable hearing solutions, today announces FDA clearance of the new Cochlear® ...
Researchers at The University of Texas MD Anderson Cancer Center have created a comprehensive single-cell map of the tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results